1. Somatomedin (SM; sulphation factor) activity was estimated by a chick-cartilage assay in fasting sera from twenty-one patients with chronic liver disease.
liver disease and its relationship to fasting serum growth hormone and biochemical liverfunction tests.
PATIENTS A N D METHODS
Sixteen men and five women with chronic liver disease were studied. Ten patients had micronodular cirrhosis, eight had hepatofibrosis, two had fatty change and one a hepatoma. In all instances the diagnosis was confirmed by liver biopsy. Alcoholism was the aetiological factor in all cases. Further clinical features are summarized in Table 1 . Blood samples were obtained from all patients by venepuncture in the recumbent position after an overnight fast. At the time of blood sampling the patients had been taking part in normal ward activities and not previously rested in bed. Serum SM activity was estimated by a chick cartilage assay (Hall, 1970; Grant, Hambley, Becker & Pimstone, 1973) . Pelvic rudiments from 11 day chick embryos were incubated in the presence of 5% and 20% test serum for 18 h and the incorporation of 35S was used to estimate proteoglycan synthesis. In each experiment, the test sera were compared with a pooled reference serum from three healthy adults, methods described by Finney (1 964) being used to check the dose-response lines for lack of parallelism and estimate the potency of the test samples relative to the reference serum. Serum growth hormone was estimated by double-antibody radioimmunoassay (Morgan & Lazarow, 1963) with the World Health Organisation Immunoreactive Protein used as standard.
Standard laboratory methods were used to determine serum albumin, total iron-binding capacity, alkaline phosphatase (EC 3.1.3. l), total bilirubin and aspartate aminotransferase (EC 2.6.1 .l) and y-glutamyltransferase (y-glutamyl transpeptidase; EC 2.3.2.2).
As the values for growth hormone, bilirubin, alkaline phosphatase, aspartate aminotransferase and y-glutainyltransferase were not normally distributed, logarithmic conversion of these results was carried out before calculation of correlation coefficients.
RESULTS
Serum SM. The serum SM results are given in Table 2 . In nine patients with cirrhosis, one patient with hepatofibrosis and the single patient with hepatoma, the SM values were significantly lower than the pooled serum from three normal adults. In general, the lowest SM values were obtained in the five patients with ascites. In the remaining ten patients, serum SM did not differ significantly from the reference value. Serum samples from the two patients with the lowest SM values (patients 8 and 21) were tested for inhibitory effects in the assay by re-assaying the control serum in their presence. No consistent inhibition of the activity of the control serum was found.
Serum growth hormone. These values, obtained after an overnight fast, are given in Table 2 . Seven patients had serum growth hormone values above 10 fiunits/ml. All these patients had serum SM values below the reference value and for the group of patients as a whole there was a significant negative correlation between serum somatomedin and growth hormone (Table 3 Serum albumin. Six patients, three of whom had ascites, had serum albumin concentrations at or below 35 g/l. Five of these patients showed low serum SM activities and there was a significant association between reduced serum somatomedin and low serum albumin (Table 3 , Fig. 2 ). There was also a significant negative correlation between serum albumin and growth hormone (Table 3) .
Serum total iron-binding capacity. The only patient with total iron-binding capacity below 40 pmol/l (patient 18) had normal serum SM activity and for the group of patients the correlation coefficient between serum SM and total iron-binding capacity barely reached statistical siflcanee (Table 3 ). There was no significant correlation between serum and growth hormone (P>0*05). Serum total bilirubin. Serum total bilirubin concentrations above 15 fimol/l(O*9 rng/lOO ml) were found in eight patients. There was a significant association between elevated serum bilirubin and both reduced serum SM and elevated serum growth hormone (Table 3) . Serum alkaline phosphatase. Serum alkaline phosphatase values above 85 munitslml were found in six of the patients with cirrhosis, two of the patients with hepatofibrosis and the single patient with hepatoma. A significant negative correlation between alkaline phosphatase and serum somatomedin activity was found (Table 3) .
Serum aspartate aminotransferase and y-glutamyltransferase. Ten patients had aspartate aminotransferase activities above 35 munits/ml and y-glutamyltransferase activities were elevated above 60 munits/ml in all but two of the seventeen patients in whom it was measured. There was no significant correlation between these enzymes and SM or growth hormone concentrations (f50.05). 
DISCUSSION
The above results indicate that serum somatomedin (SM) activity is reduced in some patients with chronic liver disease. In general, the lowest values were found in those patients who had the most severe disturbance of liver function, as judged either on clinical findings or on biochemical tests. In some patients, the serum SM levels were reduced to the levels expected in subjects with growth hormone deficiency, but serum growth hormone was, in fact, elevated in these patients. These findings suggest that the liver may be an important site for SM synthesis in man and are in agreement with results obtained in animals. Uthne & Uthne (1972) have shown that rat serum SM falls after partial hepatectomy and returns to normal as the liver regenerates. In addition, SM is generated when broken-cell preparations of rat liver are incubated with growth hormone in uitro (Hall & Uthne, 1971 ) and is released from perfused rat liver in the presence of growth hormone (McConaghey & Sledge, 1970) . The present findings are also in keeping with earlier findings of reduced serum atypical or 'non-suppressible' insulin-like activity in patients with cirrhosis (Samaan, Stillman & Fraser, 1962) , as it is now widely believed that SM activity and non-suppressible insulin-like activity are mediated by the same serum components (Hall & Uthne, 1971) .
Although the close correlation between reduced SM activities and abnormal liver function tests strongly suggests that the findings are directly related to impaired liver-cell function, the above results could also be related to other factors. Wiedmann & Schwartz (1972) have reported that serum SM activity decreases in acromegalic patients after short-term oestrogen therapy, despite persistently elevated concentrations of growth hormone. Conversely, in patients with growth hormone deficiency, pre-treatment with oestrogen prevents the rise in SM which usually follows injection of growth hormone. It therefore appears that oestrogens may inhibit the effects of growth hormone on SM synthesis or release. It is known that oestrogen metabolism is abnormal in some patients with chronic liver disease (Brown, Crean & Ginsberg, 1964) and this might account for the low SM activities described above. Plasma oestrogen levels were not studied in our patients. However, there appeared to be no obvious correlation between clinical evidence of oestrogen excess, such as gynaecomastia, and reduced serum SM activity.
Grant et ul. (1973) have reported reduced serum SM activity in severely malnourished children and malnutrition has been a common feature in many of the published accounts of alcoholism, particularly from the United States. Although all our patients had alcoholic liver disease, they showed little clinical evidence of malnutrition and we do not believe that our findings can be explained on this basis.
It is well known that some serum samples are inhibitory in assay systems for SM and as a result apparently low values for serum SM activity are obtained. In the present work we were unable to obtain evidence that such inhibitors were present. However, for technical reasons it is almost impossible to eliminate this possibility. The dose-response slopes given by the test sera did not differ significantly from that for the reference serum and OUT results have been expressed relative to this reference serum. However, it should be emphasized that present assay techniques are still imprecise, and there is also evidence that at least two different serum components are responsible for SM activity (Uthne, 1973) .
The modest elevation of serum growth hormone found in some of our patients is in keeping with some of the previous observations on patients with cirrhosis. Hernandez, Zorrilla & Gershberg (1969) and Samaan, Stone & Eckhardt (1969) found elevated fasting concentrations of growth hormone, which were not suppressed by oral glucose, and Stocks & Powell (1972) demonstrated exaggerated responses of serum growth hormone to hypoglycaemia. The exact cause of these abnormal concentrations of growth hormone is still uncertain. Owens, Srivastava, Tompkins, Nabarro & Sonksen (1973) found that the half-life of exogenous growth hormone was prolonged in most of their patients with chronic liver disease and that in patients with a normal growth hormone-distribution space, the metabolic clearance rate was reduced. However, Taylor, Lipman & Mintz (1971) , with blood samples from the brachial artery and hepatic vein, found that the hepatic clearance of "'I-labelled growth hormone was normal in four patients with cirrhosis. It has been known for some years that oestrogen therapy leads to moderate elevation of concentration of fasting serum growth hormone in normal subjects and this may account for the abnormal growth hormone findings in liver disease. Tanner (1972) suggested that serum SM may have an inhibitory role in controlling release of growth hormone. Our findings of reduced serum SM activity and elevated serum growth hormone concentration in some patients, which are similar to results already described in children with familial 'endorgan unresponsiveness' to growth hormone (Laron, Pertzelan, Karp, Kowadlo-Silbergeld & Daughaday, 1971) or with severe malnutrition (Grant et al., 1973) , would be in keeping with this hypothesis.
The concept that SM plays an important role in mediating the metabolic effects of growth hormone is becoming widely accepted, although it still has little direct experimental support (Daughaday et ul., 1972) . If this is indeed the case, our findings might explain why patients with cirrhosis and elevated serum concentrations of growth hormone do not develop acromegaly. More important, the results may provide a clue as to the cause of the muscle wasting and loss of bone mass, which are commonly found in patients with severe liver disease. In previous clinical studies on SM activities in children, low values have almost invariably been associated with delayed growth. Our finding in adults is in keeping with the severe growth retardation commonly seen in the children with liver disease, but would not account for the enhanced stature described in some adolescents with chronic liver disease (Sherlock, 1968) .
